CN102058699A - Medicine for treating pneumoconiosis - Google Patents
Medicine for treating pneumoconiosis Download PDFInfo
- Publication number
- CN102058699A CN102058699A CN 201010612862 CN201010612862A CN102058699A CN 102058699 A CN102058699 A CN 102058699A CN 201010612862 CN201010612862 CN 201010612862 CN 201010612862 A CN201010612862 A CN 201010612862A CN 102058699 A CN102058699 A CN 102058699A
- Authority
- CN
- China
- Prior art keywords
- medicine
- pneumoconiosis
- treatment
- parts
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicine for treating pneumoconiosis, which has simple preparation method and low cost. Zinc gluconate, piperaquine phosphate, tilorone dihydrochloride and traditional Chinese medicinal herbs fourstamen prismatomeris root and licorice are used as main ingredients of the medicine. The medicine is orally administered in the form of tablets, so as to be convenient in carrying and administration for patients. Meanwhile, the medicine has good curative effect on pneumoconiosis, and is suitable for pneumoconiosis patients at various ages and stages.
Description
Technical field
The present invention relates to a kind of medicine, be specifically related to a kind of medicine for the treatment of pneumoconiosis.
Background technology
Pneumoconiosis is meant labourer in vocational activity, and what suck that a large amount of respirable dusts cause is the pulmonary disease of principal character with the proliferation of fibrous tissue because of long-term.The basic lesion of pneumoconiosis is to form silicon tuberosity and the extensive fibrosis of interstitial lung, and the silicon tuberosity that the lung tissue fibrosis forms is irreversible, must go up this disease, and development causes death because of lungs lose respiratory function at last gradually.
According to the numeral that Ministry of Public Health is announced, since the fifties in last century, reported pneumoconiosis case 607 by China's accumulative total in 2005,570 examples, this numeral is equivalent to the summation of world other countries pneumoconiosis patients, and the death of people more than 140,000 has wherein been arranged approximately, and case fatality rate is more than 20%.All kinds of report of occupational disease 12212 examples in 2005, wherein pneumoconiosis case report 9173 examples account for 75% of all kinds of occupation disease sums, and great majority are from coal and metallurgy industry.In recent years, the annual New Development pneumoconiosis of China is up to 10,000 examples, and the expert estimates that 10 years from now on to 15 years China's pneumoconiosis morbidity sums also will be the continuation ascendant trend.
The traditional Chinese medical science thinks that pneumoconiosis is to invade human body because of the promptly evil poison of dust poisonous substance, and foul smell is jammed in the heart, inhibited pulmonary QI, lung network block, and is retarded by silt and agglutinates into tuberosity.Long-term poisonous substance sucks and causes body imbalance between YIN and YANG, function disorder, disharmony between QI and blood.Impairment of dispersing and descending function of the lung, the liver failing to maintain the normal flow of QI, failure of the kidney in receiving QI, dysfunction of the spleen in transportation accumulatively wet raise phlegm, flaccidity of the heart-yang, functional activity of QI being not smooth and all cards produce.Free silicon dioxide belongs to the dry strong product of metal and stone, and the strongly fragrant liquid that can burn in lung is expectorant, but heat-transformation impairment of YIN again.
The lung being the dominator of QI, the kidney being the root of QI, with the passing of time the delay of breathing with cough must undermine in kidney, deficiency of kidney-essence is difficult to dissolve vigour, the solid then gas of aerial root is difficult to return root, cough with asthma more very, dyspnea pneumoconiosis can be divided deficiency and excess, the true person of pneumoconiosis is inhibited pulmonary QI, stagnation of QI due to depression of the liver blood stasis; Pneumoconiosis belongs to empty person, and is many owing to the heart, lung, spleen, kidney qi insufficiency of blood.Clinically excess syndrome with the passing of time QI and blood consumption hinder and can cause deficiency syndrome, can be mingled with excess syndrome, deficiency in origin and excess in superficiality in the deficiency syndrome.
The medicine of present treatment pneumoconiosis has multiple, and these medicines all have certain curative effect, but also show bigger limitation.In the past pneumoconiosis treatment was adopted single variety more, for example (,) medicines such as zinc gluconate, piperaquine phosphate, Teroo hydrochloride, xanthorrhiza, drug effect was not good when these medicines used separately, and overall therapeutic effect can not be satisfactory; Also have the pure Chinese medicinal formulae of some treatment pneumoconiosis, some belongs to cures the symptoms, not the disease, and some uses expensive composition, because uncertain therapeutic efficacy is cut interrupts using, the using method of some is comparatively loaded down with trivial details in addition is not suitable for using on a large scale in application process for some.In a word, the associating side's medicine that always lacks a kind of effective treatment pneumoconiosis.
Summary of the invention
For solving the various difficult problems of above-mentioned treatment pneumoconiosis, the invention provides a kind of medicament composing prescription of new treatment pneumoconiosis, adopt zinc gluconate, piperaquine phosphate, Teroo hydrochloride and traditional Chinese herbal medicine xanthorrhiza, Radix Glycyrrhizae to make tablet, adopt oral method, can effectively treat the pneumoconiosis that a variety of causes causes, easy to use, cheap and be free from side effects.
It is clean that basic treatment theory of the present invention is that the sputum expectoration that makes the patient comes, coughs, allow the patient no longer chest pain, uncomfortable in chest, breathe hard, improved patient's sleep simultaneously, improve patient's immunity, strengthen patient's body constitution.
According to above basic treatment theory, the each component of the medicine of this treatment pneumoconiosis, its proportioning is: the each component of this medicine is according to the weight portion meter, and its proportioning is: zinc gluconate 40-60 part, piperaquine phosphate 0.1-0.3 part, Teroo hydrochloride 1-3 part, xanthorrhiza 5-8 part, Radix Glycyrrhizae 3-9 part.
With above each component material medicine mix homogeneously proportionally, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after pulverizing is made tablet, and per 30 is one bottle, is packaged as finished product.
Instructions of taking: adopt orally, take a slice, every day three times at every turn.Taking 15 days-30 days is a course of treatment.Generally taking can have remarkable result 3 courses of treatment.
Through the studying for a long period of time and manufacturing experimently of inventor, when the proportioning of finally having found above-mentioned Chinese medicine was following value, the effect of treatment was best, and the weight portion of this proportioning is: 50 parts of zinc gluconate, 0.2 part of piperaquine phosphate, 2 parts of Teroo hydrochlorides, 8 parts of xanthorrhizas, 5 parts in Radix Glycyrrhizae.
The present invention has and suppresses the pneumoconiosis pathological changes, protection macrophage, anti-silicon dioxide cytotoxicity, effects such as antibiotic and anti-hemolysis.The main effect of its main component is:
Zinc gluconate proves that through a large amount of zooperies and clinical observation on the therapeutic effect said preparation can obviously improve the subjective symptoms and the pulmonary ventilation function of pneumoconiosis patients, and human body immunity improving power and oxidation resistance suppress or delay PD.In addition, respiratory system diseases such as tracheitis, bronchitis and flu all there is certain preventive and therapeutic effect.The back sleep of taking medicine improves, and appetite increases, obviously reduce before times of common cold is taken medicine, cough, expectoration, uncomfortable in chest, breathing hard alleviates, the doing well,improving rate reaches 100%.
Piperaquine phosphate has certain curative effect to experimental pneumoconiosis, and comparatively obvious with early stage administration curative effect, has characteristics such as long-acting low toxicity.The pneumoconiosis patient all there are curative effects such as in various degree body constitution enhancing, times of common cold minimizing, biochemical index improvement.
Teroo hydrochloride is the first kind Western medicine of China's initiative.Clinical observation on the therapeutic effect is the result show: symptom the take an evident turn for the better effects such as cough, expectoration, chest pain and dyspnea of Teroo hydrochloride to improving the patient, patient's flu and bronchus pulmonary infect frequency and obviously reduce, patient's pulmonary ventilation function (FVC and FEV1) is significantly increased, the clinical symptoms of improving the pneumoconiosis patient is arranged, human body immunity improving power, strengthen pulmonary ventilation function, and delay the curative effect effect of pneumoconiosis lesion growth.Great advantage is that the clinical adverse that causes is not obvious, clinical practice safety.
Xanthorrhiza treatment pneumoconiosis effective ingredient is an aluminium-containing substance, and the lesion growth of delaying is arranged, and improves patient symptom, Signs, adjusting immunologic function, stablizes the state of an illness, prolongs patient's life-span.Xanthorrhiza has therapeutical effect to pneumoconiosis, can resist the hemolytic toxicity of quartz, asbestos, and it is lighter to show as interstitial pulmonary fibrosis, the tuberosity rareness, and profile is little, and collagen fiber are seldom in the specific stain finding tuberosity.Xanthorrhiza can be protected the macrophage of liver at liver, promotes the foreign body of liver to get rid of, thereby suppresses the formation of liver fiber effectively.Xanthorrhiza has that slight inhibition peptide chain is crosslinked to be the effect of collagen, makes collagen structure loose.
The Radix Glycyrrhizae invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.The weakness of the spleen and stomach that is used for the treatment of pneumoconiosis, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, cushion toxicity, strong.Strong, the coordinating the actions of various ingredients in a prescription of mediation other drug.
Innovative point of the present invention is associating, an amount of, cycle, rule, rule and omnidistance medication.The characteristics and the advantage of this prescription are: 1, unite the reasonable associating that is meant Chinese medicine, Western medicine, the performance synergism, make drug influence produce superposition, can prolong acting duration, improve curative effect, help by different pharmacology mechanism, intervene the multiple mechanism of pneumoconiosis simultaneously, curative effect is good than single drug, can play the summation action of 1+1=2 and the synergism of 1+1＞2, improve dust removing effects, increase curative effect.Single therapy can only obtain the part curative effect, and therapeutic alliance benefits maximum, can increase the synergism of medicine, reaches ideal effect, can also effectively prevent the untoward reaction that single therapy causes.2, be meant that in right amount employing can bring into play the dosage that effective antidusting can reduce toxicity again.Drug combination obviously reduces adverse reaction rate and degree owing to reduced the dosage and the mutual restriction of dissimilar medicine of every kind of medicine.This drug combination generally only needs the low dose of every kind of medicine, has particularly reduced the amount of individual drug such as piperaquine phosphate, Teroo hydrochloride and xanthorrhiza, has reduced toxic and side effects, and adverse reaction rate is low.This prescription has preferably adopted the optimal dose and the usage of medicine, increases dose intensity to greatest extent to reach.3, the selected component of this associating prescription requires to implement by rational blanking time, has avoided the associating of main toxicity, the overlapping medicine of mechanism of action effectively.The effective prolong drug of the medication combined application of the gram dirt action time of different blood peak concentration of drug effect times; 4, rule is meant therapeutic scheme medication in accordance with regulations, finishes and treats the course of treatment, to reduce anaphylaxis.Under the prerequisite that the most responsive normal structure of lung tissue is recovered, according to medicining cycle blanking time, can reduce dose intensity as far as possible because prolong period interval time.5, whole process: the compliance that is meant patient is eager to excel, and patient's therapeutic scheme is in accordance with regulations finished the course of treatment, and this is the key that can pneumoconiosis be alleviated and take a turn for the better, otherwise can cause the failure of treatment.6, improve benefit-cost ratio, can reduce expense.Single therapy is just selected a certain medicine for use, if when invalid or the untoward reaction that occurs tolerating, uses another kind of medicine again instead, no matter from gram dirt effect, still from exploring active drug and spent time of dosage thereof, single therapy is all little desirable, more uneconomical.
Through clinical verification for many years, medicine provided by the present invention has quick permeation, absorbs fast, rapid-action characteristics, and patients with mild is recovered 2～3 courses of treatment substantially, and moderate patient is alleviated for 3～5 courses of treatment substantially, and severe patient is general, and can take effect 5～8 courses of treatment.Therapeutic process roughly is divided into following three phases:
Phase I: remission phase
Cough with asthma alleviates, and sputum is weakened by thickness, is shoaled by black, and amount of expectoration increases on the contrary, alleviations of panting, breathe comparatively smooth and easy, but the patient changes the semireclining position rest into by not lying low.Sleep improves, and anoxia cyanosis phenomenon is obviously alleviated.
Second stage: repairing and treating phase
The impaired place of respiratory mucosa obtains repairing, and cough stops, the time a small amount of clearing away phlegm is arranged, asthma is calmed down, (still have not obvious anoxia performance as the severe patient, mouth, lip, finger tip be cyanosis slightly but respiratory drive is still not enough.Respiratory frequency is faster than ordinary person), appetite, sleep recover normal, and muscle power strengthens, and can carry out orthobiosis.Meet various risk factors, cough with asthma no longer recurs.
Phase III: rehabilitation consolidation
Respiratory mucosa renews comprehensively, obtains a lung that takes on an entirely new look.Respiratory drive is abundant, and anoxia phenomenon is removed fully, and it is sedate, strong, light to breathe.The visible down two lungs of X line are full, and elastic force is pure, and vital capacity improves 20%.
Medicine medication provided by the present invention is accurate, effect is remarkable, it is the medicine of researching and developing at the pneumoconiosis patient specially, accomplished that special disease specially controls, adopt Drug therapy pneumoconiosis provided by the present invention, its rehabilitation course is an appreciable process, and sputum increases when beginning to take, the expectorant of expectoration is sticking expectorant, black expectorant, purulent sputum, reduce to sputum, but cough, breathe heavily progressively and stop, disappearing all that physical experience arrives.After the rehabilitation, take one to three course of treatment again, just can eliminate hidden danger, consolidate curative effect, remission.
Through clinical experiment, after Most patients is taken 1-3 the course of treatment, patient's cough, cough up phlegm, symptoms such as chest pain and dyspnea obviously improve, patient's flu and bronchus pulmonary infect obviously minimizing; X line rabat pathological changes is in and takes a turn for the better or steady statue; Pulmonary ventilation function after the treatment is significantly increased before treating.
Improvement from clinical symptoms, the improvement of rabat, vim and vigour improve these multi-target effects, can prove to improve 3 kinds of Western medicine that pulmonary ventilation is a core, cooperate hard masses softening and resolving, promoting blood circulation to remove obstruction in the collateral, removing food stagnancy reduces phlegm, dispersing and descending lung-QI, regulate 2 kinds of treatments by Chinese herbs of the function of lung spleen kidney, can impel pneumoconiosis patient body to rebuild the interior environment of an optimum harmony: to strengthen the tolerance of dust cell to dust, suppress the gathering of collagen protein, improve the microcirculation of important organs such as lung kidney, enhance metabolism, softening, decompose the pulmonary fibrosis tuberosity, suppress autoimmune reaction, improve cellular immunization, separate gas removing pipe, bronchospasm, improve pulmonary ventilation and pulmonary gas exchange, alleviate the kidney injury that the autoantigen antibody complex causes, improve renal function, thereby improve the cough with asthma of pneumoconiosis, breast is suppressed, cough up phlegm, easy catching a cold, many symptoms such as the invisible nephropathy that easily occurs together.
In sum, the medicine of treatment pneumoconiosis provided by the present invention is part Western medicine and parts of traditional Chinese medicine owing to what adopt, and is cheap, can promote the use of on a large scale; Owing to adopt xanthorrhiza, the Chinese medicine of licorice root material of pure natural, reduced side effects of pharmaceutical drugs; Adopt the packing of tablet, both made things convenient for daily taking, be convenient for carrying medication at any time again, the misery when the alleviation patient falls ill is fit to each phase pneumoconiosis patient of various age brackets and takes; Treatment time is short, instant effect.
The specific embodiment
Embodiment 1
A kind of medicine for the treatment of pneumoconiosis, each component are according to the weight portion meter, and its proportioning is: 40 parts of zinc gluconate, 0.2 part of piperaquine phosphate, 1.5 parts of Teroo hydrochlorides, 9 parts of xanthorrhizas, 4 parts in Radix Glycyrrhizae.
With above each component material medicine mix homogeneously, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after sieving is made tablet, and per 30 is one bottled for finished product.
In the above-mentioned prescription, every part is 1g.
Embodiment 2
A kind of medicine for the treatment of pneumoconiosis, each component are according to the weight portion meter, and its proportioning is: 50 parts of zinc gluconate, 0.15 part of piperaquine phosphate, 1 part of Teroo hydrochloride, 8 parts of xanthorrhizas, 9 parts in Radix Glycyrrhizae.
With above each component material medicine mix homogeneously, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after sieving is made tablet, and per 30 is one bottled for finished product.
In the above-mentioned prescription, every part is 5g.
Embodiment 3
A kind of medicine for the treatment of pneumoconiosis, each component are according to the weight portion meter, and its proportioning is: 60 parts of zinc gluconate, 0.1 part of piperaquine phosphate, 3 parts of Teroo hydrochlorides, 5 parts of xanthorrhizas, 7 parts in Radix Glycyrrhizae.
With above each component material medicine mix homogeneously, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after sieving is made tablet, and per 30 is one bottled for finished product.
In the above-mentioned prescription, every part is 5g.
Embodiment 4
A kind of medicine for the treatment of pneumoconiosis, each component are according to the weight portion meter, and its proportioning is: 45 parts of zinc gluconate, 0.25 part of piperaquine phosphate, 2.5 parts of Teroo hydrochlorides, 10 parts of xanthorrhizas, 3 parts in Radix Glycyrrhizae.
With above each component material medicine mix homogeneously, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after sieving is made tablet, and per 30 is one bottled for finished product.
In the above-mentioned prescription, every part is 3g.
Embodiment 5
A kind of medicine for the treatment of pneumoconiosis, each component are according to the weight portion meter, and its proportioning is: 55 parts of zinc gluconate, 0.3 part of piperaquine phosphate, 2 parts of Teroo hydrochlorides, 7 parts of xanthorrhizas, 5 parts in Radix Glycyrrhizae.
With above each component material medicine mix homogeneously, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after sieving is made tablet, and per 30 is one bottled for finished product.
In the above-mentioned prescription, every part is 10g.
Embodiment 6
A kind of medicine for the treatment of pneumoconiosis, each component are according to the weight portion meter, and its proportioning is: 50 parts of zinc gluconate, 0.2 part of piperaquine phosphate, 2 parts of Teroo hydrochlorides, 8 parts of xanthorrhizas, 5 parts in Radix Glycyrrhizae.
With above each component material medicine mix homogeneously, be ground into coarser powder jointly, coarser powder is crossed the 50-100 mesh sieve, and the thick medicamental pulverata after sieving is made tablet, and per 30 is one bottled for finished product.
In the above-mentioned prescription, every part is 5g.
Experimental example 1
Guo patient, the man, 68 years old, III phase pneumoconiosis, the pulmonary function second phase, provide through the inventor, take the medicine of the treatment pneumoconiosis that makes according to the embodiment of the invention 2 described proportionings and method, an a slice, three times on the one, course of treatment on the 30th.Interval 30 days, second course of treatment again.Continuous three courses of treatment.The patient reacts well, has no side effect, and symptom is significantly alleviated.
Experimental example 2
Patient's Qi, the man, 71 years old, II phase pneumoconiosis, the pulmonary function second phase, provide through the inventor, take the medicine of the treatment pneumoconiosis that makes according to the embodiment of the invention 1 described proportioning and method, an a slice, a twice-daily, course of treatment on the 30th.Interval 30 days, second course of treatment again.Continuous two courses of treatment.Patient's sx has no side effect.
Experimental example 3
The patient cattle, the man, 59 years old, I phase pneumoconiosis, the pulmonary function second phase, provide through the inventor, take the medicine of the treatment pneumoconiosis that makes according to the embodiment of the invention 3 described proportionings and method, an a slice, once a day, course of treatment of 30 orders.Interval 30 days, second course of treatment again.Continuous three courses of treatment.Patient's transference cure has no side effect.
During with drug test provided by the present invention, treatment group pneumoconiosis patient 157 examples, every day, oral medicine provided by the present invention was 3, treated altogether 12 months; Matched group patient 88 examples are taken placebo (not containing the alike starch sheet of any pharmaceutical component, profile and medicine provided by the present invention).The result shows, treatment group patient's cough, cough up phlegm, symptoms such as chest pain and dyspnea obviously improve, effective percentage is respectively 62.0%～73.0%; Patient's flu and bronchus pulmonary infect obviously and reduce; X line rabat pathological changes is in and takes a turn for the better or steady statue, compares difference significance (P＜0.05) with matched group; Pulmonary ventilation function after the treatment (FVC and FEV1) is significantly increased (P＜0.01) before treating.The above results shows that medicine provided by the present invention has significant curative effect.
Claims (4)
1. medicine for the treatment of pneumoconiosis, it is characterized in that: the each component of this medicine is according to the weight portion meter, and its proportioning is: zinc gluconate 40-60 part, piperaquine phosphate 0.1-0.3 part, Teroo hydrochloride 1-3 part, xanthorrhiza 5-10 part, Radix Glycyrrhizae 3-9 part;
Its processing method is: above each component material medicine is even according to the prescription mixed, and be ground into coarser powder jointly, sieve, the thick medicamental pulverata after sieving is made tablet, per 30 is one bottle, is packaged as finished product.
2. the medicine of treatment pneumoconiosis according to claim 1 is characterized in that: the each component of this medicine is according to the weight portion meter, and its proportioning is: 50 parts of zinc gluconate, 0.2 part of piperaquine phosphate, 2 parts of Teroo hydrochlorides, 8 parts of xanthorrhizas, 5 parts in Radix Glycyrrhizae.
3. the method for the medicine of pneumoconiosis is treated in processing according to claim 1, it is characterized in that: above each component material medicine is even according to the prescription mixed, be ground into coarser powder jointly, sieve, the thick medicamental pulverata after sieving is made tablet, per 30 is one bottle, is packaged as finished product.
4. processing method according to claim 3 is characterized in that: the coarser powder after the pulverizing is crossed the 50-100 mesh sieve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106128621A CN102058699B (en) | 2010-12-29 | 2010-12-29 | Medicine for treating pneumoconiosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106128621A CN102058699B (en) | 2010-12-29 | 2010-12-29 | Medicine for treating pneumoconiosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058699A true CN102058699A (en) | 2011-05-18 |
| CN102058699B CN102058699B (en) | 2012-05-09 |
Family
ID=43994324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106128621A Expired - Fee Related CN102058699B (en) | 2010-12-29 | 2010-12-29 | Medicine for treating pneumoconiosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058699B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103896802A (en) * | 2012-12-27 | 2014-07-02 | 江苏伯克生物医药股份有限公司 | Drug for preventing and treating pulmonary fibrosis and its production and quality detection methods |
| CN104958351A (en) * | 2015-06-29 | 2015-10-07 | 济南正骐生物科技有限公司 | Pharmaceutical composition for treating pneumoconiosis |
| WO2017031657A1 (en) * | 2015-08-24 | 2017-03-02 | 济南正骐生物科技有限公司 | Medicine composition for treating pneumoconiosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116936A (en) * | 1994-08-19 | 1996-02-21 | 江西弋阳制药厂 | Xifukang Chinese herb medicine compound preparation for silicosis and its preparing method |
| CN1328847A (en) * | 2001-07-05 | 2002-01-02 | 高树良 | Chinese medicine preparation for curing pneumoconiosis |
| CN1381252A (en) * | 2002-04-29 | 2002-11-27 | 史艳梅 | Chines medicine for treating silicosis |
| CN101780167A (en) * | 2009-01-15 | 2010-07-21 | 王峰 | Chinese medicine compound for preventing and curing lung diseases and clearing human body toxin and preparation method thereof |
-
2010
- 2010-12-29 CN CN2010106128621A patent/CN102058699B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116936A (en) * | 1994-08-19 | 1996-02-21 | 江西弋阳制药厂 | Xifukang Chinese herb medicine compound preparation for silicosis and its preparing method |
| CN1328847A (en) * | 2001-07-05 | 2002-01-02 | 高树良 | Chinese medicine preparation for curing pneumoconiosis |
| CN1381252A (en) * | 2002-04-29 | 2002-11-27 | 史艳梅 | Chines medicine for treating silicosis |
| CN101780167A (en) * | 2009-01-15 | 2010-07-21 | 王峰 | Chinese medicine compound for preventing and curing lung diseases and clearing human body toxin and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 《中国煤炭工业医学杂志》 20090920 蒲新明等 尘肺病防治的研究概况 第12卷, 第09期 2 * |
| 《工业卫生与职业病》 19930720 严川信等 葡萄糖酸锌对大鼠矽肺早期病变的影响 第19卷, 第04期 2 * |
| 《江西医药》 20041021 戚京城等 矽肺治疗药物的进展 第39卷, 第05期 2 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103896802A (en) * | 2012-12-27 | 2014-07-02 | 江苏伯克生物医药股份有限公司 | Drug for preventing and treating pulmonary fibrosis and its production and quality detection methods |
| CN104958351A (en) * | 2015-06-29 | 2015-10-07 | 济南正骐生物科技有限公司 | Pharmaceutical composition for treating pneumoconiosis |
| WO2017031657A1 (en) * | 2015-08-24 | 2017-03-02 | 济南正骐生物科技有限公司 | Medicine composition for treating pneumoconiosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058699B (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102475863A (en) | Chinese medicine for treating chronic bronchitis | |
| CN102058699B (en) | Medicine for treating pneumoconiosis | |
| CN103071047B (en) | Decoction for treating silicosis and preparation method thereof | |
| JP6129314B2 (en) | Composition for the treatment of cancer-related fatigue | |
| KR100809584B1 (en) | Composition for preventing and treating inflammatory disease comprising glucosamine and pinitol | |
| CN105288406A (en) | Traditional Chinese medicine preparation for treating bronchitis due to deficiency of both lung and spleen as well as preparation method thereof | |
| CN101926903A (en) | Chinese medicine preparation for curing facial paralysis | |
| CN104958351A (en) | Pharmaceutical composition for treating pneumoconiosis | |
| CN103040940A (en) | Traditional Chinese medicine composition for treating common cold due to wind-cold | |
| CN105833034A (en) | Traditional Chinese medicine composition | |
| CN104758884A (en) | Traditional Chinese medicine composition for treating asthma | |
| CN105687757A (en) | Traditional Chinese medicine composition for treating phlegm-qi stagnation type hyperthyreosis with automatic junctional tachycardia | |
| CN102397319A (en) | Medicament for treating pertussis | |
| CN101721478B (en) | Medicine for treating infantile diarrhea | |
| CN105616994A (en) | Traditional Chinese medicine composition for treating liver yin deficiency type cardiovascular neurosis | |
| CN104435636B (en) | A kind of Chinese medicine composition for preventing paracmasis chronic bronchitis to recur | |
| CN102370818A (en) | Chinese medicinal composition for treating fatty liver | |
| CN100496574C (en) | An externally applied Chinese herbal composition for treating scapulohumeral periarthritis | |
| CN105748783A (en) | Drug for treating asthma | |
| CN111956758A (en) | Pharmaceutical composition and preparation for treating recurrent oral ulcer and preparation method thereof | |
| CN110251565A (en) | A kind of liquid medicine of cure scapulohumeral periarthritis and preparation method thereof | |
| CN109091654A (en) | A kind of method of cloves treatment chronic gastritis | |
| CN105687744A (en) | Traditional Chinese medicine composition for treating liver-yin depletion type hyperthyroidism complicating automatic atrial tachycardia | |
| CN102008701A (en) | Chinese medicinal composite for treating lung heat | |
| CN107007805A (en) | Treat the composition and a kind of pack and a kind of preparation method of spray of flu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 Termination date: 20121229 |